Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation
Abstract Mesenchymal stem cells (MSCs) have natural immunoregulatory functions that have been explored for medicinal use as a cell therapy with limited success. A phase Ib study was conducted to evaluate the safety and immunoregulatory mechanism of action of MSCs using a novel ex vivo product (SBI‐1...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/972534fc7b2b461b98b88dca1a0d590f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:972534fc7b2b461b98b88dca1a0d590f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:972534fc7b2b461b98b88dca1a0d590f2021-12-03T12:11:46ZPharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation2157-65802157-656410.1002/sctm.21-0043https://doaj.org/article/972534fc7b2b461b98b88dca1a0d590f2021-12-01T00:00:00Zhttps://doi.org/10.1002/sctm.21-0043https://doaj.org/toc/2157-6564https://doaj.org/toc/2157-6580Abstract Mesenchymal stem cells (MSCs) have natural immunoregulatory functions that have been explored for medicinal use as a cell therapy with limited success. A phase Ib study was conducted to evaluate the safety and immunoregulatory mechanism of action of MSCs using a novel ex vivo product (SBI‐101) to preserve cell activity in patients with severe acute kidney injury. Pharmacological data demonstrated MSC‐secreted factor activity that was associated with anti‐inflammatory signatures in the molecular and cellular profiling of patient blood. Systems biology analysis captured multicompartment effects consistent with immune reprogramming and kidney tissue repair. Although the study was not powered for clinical efficacy, these results are supportive of the therapeutic hypothesis, namely, that treatment with SBI‐101 elicits an immunotherapeutic response that triggers an accelerated phenotypic switch from tissue injury to tissue repair. Ex vivo administration of MSCs, with increased power of testing, is a potential new biological delivery paradigm that assures sustained MSC activity and immunomodulation.Madhav SwaminathanNelson KopytMohamed G. AttaJai RadhakrishnanKausik UmanathSunny NguyenBrian O'RourkeAshley AllenNatalie VaninovArno TillesElizabeth LaPointeAndrew BlairChris GemmitiBrian MillerBiju ParekkadanRita N. BarciaWileyarticleadult stem cellscellular therapyclinical trialscytokinesimmunotherapylymphocytesMedicine (General)R5-920CytologyQH573-671ENStem Cells Translational Medicine, Vol 10, Iss 12, Pp 1588-1601 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
adult stem cells cellular therapy clinical trials cytokines immunotherapy lymphocytes Medicine (General) R5-920 Cytology QH573-671 |
| spellingShingle |
adult stem cells cellular therapy clinical trials cytokines immunotherapy lymphocytes Medicine (General) R5-920 Cytology QH573-671 Madhav Swaminathan Nelson Kopyt Mohamed G. Atta Jai Radhakrishnan Kausik Umanath Sunny Nguyen Brian O'Rourke Ashley Allen Natalie Vaninov Arno Tilles Elizabeth LaPointe Andrew Blair Chris Gemmiti Brian Miller Biju Parekkadan Rita N. Barcia Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| description |
Abstract Mesenchymal stem cells (MSCs) have natural immunoregulatory functions that have been explored for medicinal use as a cell therapy with limited success. A phase Ib study was conducted to evaluate the safety and immunoregulatory mechanism of action of MSCs using a novel ex vivo product (SBI‐101) to preserve cell activity in patients with severe acute kidney injury. Pharmacological data demonstrated MSC‐secreted factor activity that was associated with anti‐inflammatory signatures in the molecular and cellular profiling of patient blood. Systems biology analysis captured multicompartment effects consistent with immune reprogramming and kidney tissue repair. Although the study was not powered for clinical efficacy, these results are supportive of the therapeutic hypothesis, namely, that treatment with SBI‐101 elicits an immunotherapeutic response that triggers an accelerated phenotypic switch from tissue injury to tissue repair. Ex vivo administration of MSCs, with increased power of testing, is a potential new biological delivery paradigm that assures sustained MSC activity and immunomodulation. |
| format |
article |
| author |
Madhav Swaminathan Nelson Kopyt Mohamed G. Atta Jai Radhakrishnan Kausik Umanath Sunny Nguyen Brian O'Rourke Ashley Allen Natalie Vaninov Arno Tilles Elizabeth LaPointe Andrew Blair Chris Gemmiti Brian Miller Biju Parekkadan Rita N. Barcia |
| author_facet |
Madhav Swaminathan Nelson Kopyt Mohamed G. Atta Jai Radhakrishnan Kausik Umanath Sunny Nguyen Brian O'Rourke Ashley Allen Natalie Vaninov Arno Tilles Elizabeth LaPointe Andrew Blair Chris Gemmiti Brian Miller Biju Parekkadan Rita N. Barcia |
| author_sort |
Madhav Swaminathan |
| title |
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| title_short |
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| title_full |
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| title_fullStr |
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| title_full_unstemmed |
Pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| title_sort |
pharmacological effects of ex vivo mesenchymal stem cell immunotherapy in patients with acute kidney injury and underlying systemic inflammation |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/972534fc7b2b461b98b88dca1a0d590f |
| work_keys_str_mv |
AT madhavswaminathan pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT nelsonkopyt pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT mohamedgatta pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT jairadhakrishnan pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT kausikumanath pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT sunnynguyen pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT brianorourke pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT ashleyallen pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT natalievaninov pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT arnotilles pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT elizabethlapointe pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT andrewblair pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT chrisgemmiti pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT brianmiller pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT bijuparekkadan pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation AT ritanbarcia pharmacologicaleffectsofexvivomesenchymalstemcellimmunotherapyinpatientswithacutekidneyinjuryandunderlyingsystemicinflammation |
| _version_ |
1718373283747856384 |